T he angiotensin II type 2 receptor (AT 2 R) mediates a vasodilator [1] [2] [3] cascade that includes bradykinin (BK), NO, and cGMP. BK, the major effector hormone of the kallikreinkinin system, acts mainly through the BK B 2 receptor (B 2 R) to mediate most of its cardiovascular and renal actions. Our previous data demonstrated that, compared with individual receptor contributions, simultaneous activation of AT 2 R and B 2 R led to a 70% increase in NO production, 1 suggesting interaction between these 2 receptors. However, the molecular mechanism involving the AT 2 R-B 2 R-NO pathway is unknown.
Receptor-receptor crosstalk is an essential process for plasma membrane-localized receptors, including those involving the superfamily of the 7 trans-membrane G proteincoupled receptors (GPCRs). 4 It is well established that a variety of cell surface receptors interact with each other to form dimers and that this is essential for their activation. Recent studies provided evidence for the existence of GPCR homodimers and heterodimers. 5 Heterodimerization has effects on ligand binding, receptor activation, desensitization, and trafficking, as well as receptor signaling different from those of the homodimer or oligomer. 6, 7 Heterodimerization provides a newly recognized means of modulation of receptor function, as well as cross-talk between GPCRs. We hypothesized that AT 2 R and B 2 R heterodimerize to enhance NO production. In this study, fluorescence resonance energy transfer (FRET) microscopy was used to measure the molecular proximity between AT 2 R and B 2 R in PC12W in vivo and to provide evidence for and quantification of receptor heterodimerization. To evaluate the regulation of this dimer unit, we incubated PC12W cells with agonists and/or antagonists to either AT 2 R or B 2 R. Immunoaffinity chromatography followed by immunoblotting detection was used to quantify the changes in heterodimer formation. To demonstrate functional consequences of AT 2 R-B 2 R heterodimerization, we monitored changes in intracellular phosphoprotein signaling activities that have been linked previously to classical functions of AT 2 R and B 2 R and NO and cGMP production in response to different pharmacological agents.
Methods

Cell Culture
PC12W cells (rat pheochromocytoma cells) were obtained from the American Type Culture Collection, cultured in DMEM (GIBCO) with 10% horse serum, 5% FCS, 100 U/mL penicillin, and 1 mg/mL streptomycin in a humidified atmosphere of 95% air and 5% CO 2 .
Laser Scanning Confocal FRET Microscopy and Image Analysis
For the protein localization using FRET microscopy techniques, we used the laser scanning confocal FRET (C-FRET) microscopy. 7, 8 We configured the Biorad Radiance 2100 laser scanning confocal/multiphoton microscopy system as a C-FRET system as described. 9 The system consists of a Nikon TE300 epifluorescent microscope, a Plan Fluor 100X NA 1.4 oil immersion objective lens, argon ion laser (457,488,514), HeNe 543 nm, and 633 nm (www.cellscience.bio-rad. com). This has 3 fluorescence and 1 transmission channels. Nondes-canned detectors, which can be used for multiphoton microscopy imaging, were used for both C-FRET and 2-photon excitation fluorescence resonance energy transfer (2p-FRET) image acquisition. For C-FRET, an Argon laser emitting at 488 nm was used to excite the donor fluorophore, whereas a HeNe Green laser emitting at 543 nm was used to excite the acceptor fluorophore. Emissions from the fluorophores were split using a 560-nm dichroic mirror and filtered using an HQ528/30 nm filter for the donor emission channel and an HQ590/70 nm filter for the acceptor channel (www.chromatech.com). The images from donor and acceptor channels were acquired for single-labeled (control) cells and double-labeled cells for further FRET data processing as described in the literature. 10 -14 The anti-receptor antibodies for AT 2 R or B 2 R reacted specifically with either the AT 2 R 15-17 or the B 2 R, 18 respectively. To confirm the absence of cross-reactivity of these receptor antibodies, we studied Chinese hamster ovary cells transfected with AT 2 R or B 2 R. Using a PIERCE immunoaffinity matrix with subsequent immunoblot detection, we were able to detect the AT 2 R but not the B 2 R with the AT 2 R antibody and the B 2 R but not the AT 2 R with B 2 R antibody (data not shown) in Chinese hamster ovary cells transfected with AT 2 R or B 2 R, respectively. It is noteworthy to state that there were no immunoblots detected at 110 Kd, suggesting an absence of dimerization artifacts.
Serum-starved PC12W cells expressing both AT 2 R and B 2 R (in the absence of the AT 1 receptor) were used. We determined AT 2 R and B 2 R protein levels in PC12W cells. AT 2 R and B 2 R antibodies were labeled with Alexa fluorophores 488 and 555 to demonstrate colocalization and interaction between AT 2 R and B 2 R using C-FRET microscopy as an accurate measure of molecular proximity at angstrom distances (10 to 100 Å) with higher spatial resolution beyond the limits of conventional microscopy.
Functional Assays
Bio-Plex Phosphoprotein Cellular Signaling Assays
Bead-based multiplex Luminex xMAP technology assays (Bio-Rad Laboratories) that directly detect phosphorylated proteins, c-Jun terminal kinase (JNK), phosphotyrosine phosphatase (PTP), extracellular signal-regulated kinases (1 and 2), p38 mitogen-activated protein kinases (MAPKs), activating transcription factor 2 (ATF2), signal transducer and activator of transcription 3 (STAT3), and inhibitory protein B␣ (IB␣), were used in lysates derived from cell culture using highly specific antibodies exclusively developed and validated by Cell Signaling Technology, Inc. PC12W cells were incubated with AT 2 R and B 2 R agonists or antagonists individually or combined for 24 hours. The cells were then lysed and centrifuged. Using these 96-well plate-format assays, we profiled the specific phosphorylation state of multiple proteins simultaneously in a single sample. Data from the reaction were acquired using the Bio-Plex suspension array system, a dual-laser, flow-based microplate reader system that can discriminate Յ100 different bead based assays. The contents of the wells are drawn up into the reader.
Protein Tyrosine Phosphatase
PC12W cells were incubated with AT 2 R and B 2 R agonists or antagonists individually or combined for 24 hours. The cells were then lysed and centrifuged. Protein tyrosine phosphatase activity was measured in the supernatant by using an assay kit (Takara). 19 The sensitivity is 0.125ϫ10 Ϫ5 units/L, and the specificity is 100%.
Coimmunoprecipitation and Immunoblotting of AT 2 R and B 2 R
PC12W cell groups were divided into 2 sets. The first set of cells was treated with agonists and/or antagonists to the AT 2 R and/or B 2 R for 30 minutes to test the effect of receptor activation on heterodimer formation. The second set of cells was treated with agonists and/or antagonists to the AT 2 R and/or B 2 R for 24 hours to test the effect of altering the expression of these receptors on heterodimer formation. After washing 3 times with PBS, immunoaffinity chromatography was used by anti-B 2 R antibodies or by anti-AT 2 R antibodies using a PIERCE immunoaffinity matrix.
Anti-AT 2 R and anti-B 2 R antibodies raised against the third and second extracellular loops, respectively, were used for immunoaffinity purification and subsequent immunoblot detection. Proteins were dissolved and separated by 10% SDS-PAGE under reducing conditions. B 2 R and AT 2 R were identified in immunoblot using anti-receptor antibodies.
cGMP and NO Measurements
Nitrate/nitrite and cGMP levels in cell lysate samples were measured by using an enzyme immunoassay kit. 1 The sensitivity was 2.0 mol/L and 0.09 pmol/mL for nitrate/nitrite 1 and cGMP, 3 respectively, and the specificity was 100% for both. The intra-assay and interassay cross-reactivity with other cyclic nucleotides was Ͻ0.01%.
Statistical Analysis
Data are expressed as meanϮSE. Differences between mean values of agonists and/or antagonists to the AT 2 R and/or B 2 R and vehicle were analyzed by ANOVA, with a subsequent Tukey honestly significant difference multiple-comparisons test. Differences of PϽ0.05 were considered significant.
Results
C-FRET Microscopy Study
We characterized the cell membrane site-specific distribution of AT 2 R ( Figure 1A) and B 2 R ( Figure 1B) proteins. Our results demonstrated that the average distance between AT 2 R-B 2 Rdimerized receptors is 50Ϯ5 Å, allowing the signal to be transferred from the excited molecular donor fluorophore to the acceptor fluorophore by means of intermolecular long-range dipole-dipole coupling ( Figure 1C ), thus confirming their physical association ( Figure 1D and 1E) . AT 2 R-B 2 R heterodimers were detected both on the cell membrane, as well as intracellularly mainly in the perinuclear region.
Coimmunoprecipitations and Immunoblotting
AT 2 R and B 2 R monomers and dimers were detected by their specific antibodies. In the 110 Kd dimer band, both AT 2 R and B 2 R were detected in the same blot. Treatment with agonists and/or antagonists to either AT 2 R or B 2 R for 30 minutes to influence the receptor activation state without changing the receptor expression level did not affect the level of heterodimer formation (data not shown).
The percentage change in AT 2 R and B 2 R expression and dimerization after administration of different pharmacological agents for 24 hours (Figure 2A through 2C ) is shown in Table 1 . Our results demonstrate that an increase in the expression of AT 2 R and/or B 2 R was consistently accompanied by an increase in heterodimer formation. The maximum increase in AT 2 R-B 2 R heterodimer formation was observed as a result of combined treatment of an AT 2 R agonist and a B 2 R antagonist, each individually increasing both receptors' expression and inducing a 250% increase in heterodimer formation.
( Figure 3 ). Our data (Table 2) demonstrate that pharmacological agents producing a maximum number of AT 2 R-B 2 R heterodimers selectively led to phosphorylation of JNK, PTP, IB␣, and ATF2 and dephosphorylation of p38 and p42/44 MAPK and STAT3.
Intracellular NO and cGMP Production in Response to Changes of Dimer Formation
As shown in Figure 4 , both AT 2 R and B 2 R agonists individually and combined increased NO and cGMP levels, whereas their respective antagonists decreased NO and cGMP. AT 2 R agonist CGP 42112A (Ciba Geigy) and B 2 R agonist BK increased NO and cGMP from (3.461Ϯ0.25 mol/L, 41.17ϩ3.25 pg/mL) at baseline to (9.321Ϯ1.25 mol/L; PϽ0.05, 69.5Ϯ5.7pg/mL; PϽ0.05) and (7.46Ϯ0.5 mol/L; PϽ0.05, 55.6ϩ1.8pg/mL; PϽ0.05). Antagonists to the AT 2 R (PD123319 [PD]) and B 2 R (icatibant) had no effect on the basal production of NO and cGMP. The combination of AT 2 R antagonist with either the B 2 R agonist or antagonist did not change the level of NO or cGMP as compared with the basal production level. In contrast, the addition of the AT 2 R agonist CGP to either the B 2 R agonist or antagonist increased NO production. CGP and BK combination increased NO and cGMP (9.64Ϯ0.80 mol/L; PϽ0.05, 77.3Ϯ 2.6 pg/mL; PϽ0.001). The maximum increase in NO and cGMP production (12.4Ϯ1.7 mol/L; PϽ0.001, 90.9Ϯ6.8; PϽ0.001) was persistently associated with the combination of AT 2 R stimulation and B 2 R inhibition that also led to a maximum increase in AT 2 R-B 2 R heterodimer formation with AT 2 R agonist CGP and B 2 R antagonist icatibant, respectively.
Discussion
In this study, we report the formation of a stable functional AT 2 R-B 2 R heterodimer unit. The distance between the third extracellular loop in the AT 2 R and the second extracellular loop in the B 2 R is 50Ϯ5 Å, which indicates the close molecular proximity between AT 2 R and B 2 R, providing evidence of receptor heterodimerization as the mechanism to enhance NO production. This result was supported and strengthened by the coimmunoprecipitation results, indicating that active high-affinity AT 2 R and B 2 R heterodimers were stable with no preceding cross-linking, which demonstrates the strength of the physical association between the 2 dimerized receptors. The C-FRET data demonstrated the physical association between the 2 dimerized receptors without any stimulation and suggests the presence of constitutive heterodimers. It is possible that homodimers or even heterotetramers of AT 2 R, B 2 R, and angiotensin II type 1 (AT 1 R) are formed. Because the aim of the current study was to prove the presence AT 2 R and B 2 R heterodimers, such possibilities were not studied. In addition, C-FRET demonstrated that AT 2 R-B 2 R heterodimers were detected at the plasma membrane and in the perinuclear region. This is in agreement with a recent report of AT 2 R internalization. 20 Previous studies suggested formation of dimers in the endoplasmic reticulum. 21, 22 Our study suggests active transport of the bound antibody-dimer complex from the cell surface to the intracellular compartment, because the cells were not permeabilized, and the fluorescent-labeled antibody is unable to penetrate the cell membrane. The rate of formation of the AT 2 R-B 2 R heterodimer seems to be regulated in large part by the status of AT 2 R and B 2 R expression. Treatment with agonists and/or antagonists to either AT 2 R or B 2 R for 30 minutes to influence the receptor activity state without changing the receptor expression level did not affect the level of heterodimer formation, suggesting that receptor activation does not contribute principally to the level of heterodimer formation. Our results demonstrate that an increase in the expression of AT 2 and/or B 2 receptors was consistently accompanied by an increase in heterodimer formation after administration of different pharmacological agents for 24 hours. It is noted that pharmacological agents that increased 1 type of receptor similarly affected the expression or dimer formation of the other receptor, or both, at different levels. This finding is consistent with recent studies examining the effects angiotensin II on the regulation 
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of B 2 receptors. 23 The reverse was also observed between AT 1 R and kallikrein gene therapy. 24 The maximum increase in AT 2 R-B 2 R heterodimer formation was observed as a result of combined treatment of an AT 2 R agonist and a B 2 R antagonist, each individually increasing the expression of both receptors and inducing a 250% increase in heterodimer formation. It is possible that the increase in dimer formation with PD treatment could be because of increased conversion of monomer to dimer. However, the monomer did not increase with PD treatment. Furthermore, we observed a decrease in B 2 R dimer and monomer in response to PD. Although B 2 R blockade substantially increased the AT 2 R and B 2 R expression, it only slightly increased AT 2 R-B 2 R heterodimer formation. At present, the mechanisms underlying the difference between B 2 R antagonist versus AT 2 R agonist with or without B 2 R antagonist on dimer formation observed in the current study are unknown. It is noteworthy that AT 2 R stimulation was always associated with increased dimer formation. Thus, factors that influence AT 2 R expression and activity may play a more important role in dimer formation than factors affecting B 2 R expression. In the present study, we could not determine whether all dimers present in vivo are coprecipitated in vitro. However, it is unlikely that coimmunoprecipitation promoted the partial dissociation of dimers, because all of the cell groups were exposed to same experimental conditions. Dimers were still visible under reducing conditions and boiling in SDS buffer, demonstrating the strength of physical association between the 2 dimerized receptors. The combination of FRET with immunoprecipitation studies provides an additional evidence for dimerization.
To demonstrate functional consequences of AT 2 R-B 2 R heterodimerization, we monitored changes in intracellular phosphoprotein signaling activities that have been linked previously to classical functions of AT 2 R and B 2 R, such as NO production, antiproliferative properties, and apoptosis. Simultaneous measurement of JNK, MAPK, p38 and p42/44 MAPK, STAT3, IB␣, ATF2, and PTP in response to manipulation of AT 2 R and B 2 R demonstrated that the receptor heterodimers are functional. Our data demonstrated that pharmacological agents producing the maximum number of AT 2 R-B 2 R heterodimers selectively led to phosphorylation of JNK, PTP, IB␣, and ATF2 and dephosphorylation of p38 and p42/44 MAPK and STAT3. Taken together, these receptor manipulations were associated with a 258% and 80% increase in NO and cGMP production, respectively, in agreement with recent studies on the role of these signaling pathways in the production of NO. 24 -37 JNK and ATF2 phosphorylation were highly associated with NO production when the effects of other pathways were statistically excluded (partial correlation coefficient: 0.08 and 0.31, respectively). Similarly, dephosphorylation of STAT3 was associated with NO production. It is noted that the correlation of JNK with NO production remained constant in presence or absence of contributions from other pathways, suggesting little correlation between JNK and other signaling molecules studied. This represents the first study to our knowledge to conduct an extensive signaling pathway analysis comparing molecules mediated by AT 2 R and B 2 R to influence NO production.
The maximum increase in NO and cGMP production was persistently associated with the combination of AT 2 R stimulation and B 2 R inhibition that also led to maximum increase in AT 2 R-B 2 R heterodimer formation with CGP and icatibant, respectively. This is in agreement with a recent report that B 2 R blockade further increased, rather than decreased, the 
Percentage change in AT 2 R and B 2 R expression and dimerization in response to CGP42112A (CGP, 100 nmol), PD123319 (PD, 1 mol), BK (1 mol), and icatibant (1 mol), individually or combined. Data shown are average of 3 experiments. ϩ indicates increase; Ϫ, decrease. effect of activated AT 2 R on cGMP and NO production. 38 Both B 2 R agonist and antagonist were observed to have a similar influence on NO production when combined with AT 2 R agonist. However, the mechanism of NO production because of B 2 R agonist is different from that of the antagonist. Icatibant and CGP combined administration increased the expression of both B 2 R and AT 2 R. When the B 2 R is blocked by icatibant, unopposed stimulation of the upregulated and dimerized AT 2 R via CGP is facilitated, driving NO production via the AT 2 R. Similarly, both B 2 R and AT 2 R are involved in the production of NO in the BKϩCGP combined treatment group. However, the negative influence of BK on AT 2 R and B 2 R expression and dimer formation reduced the production level of NO as compared with the icatibantϩCGP-treated group.
In conclusion, for functional enhancement of NO production, receptors must first be expressed. Dimerization occurs as a function of receptor number but also requires AT 2 R activation. This explains why icatibant alone increases B 2 R and AT 2 R expression but neither dimer formation nor NO or cGMP production.
Perspectives
In the light of our present study and recent reports of the heterodimerization between AT 1 R-AT 2 R 39 and AT 1 R-B 2 R, 40 -42 it is clear that each of these receptors may heterodimerize with 1 of the 2 other receptors. Determination of which receptors should form a heterodimer likely depends on the distribution and availability of the individual receptors. Selective induction of the AT 2 R and B 2 R expression and dimer formation presents a new therapeutic intervention target for the treatment of hypertension and other cardiovascular and renal disorders. PC12W cells were treated with icatibant (1 mol) or CGP42112A (CGP, 100 nmol) individually or combined for 24 hours. The cells were then lysed and centrifuged. The specific phosphorylation state of multiple proteins was measured simultaneously in the same treatment sample. Data acquired using the Bio-Plex suspension array system, a dual-laser, and flow-based microplate reader system. Data represent percentage change from control. Data shown are average of 3 experiments. ERK indicates extracellular signal regulated kinase. 
